

Sulfinpyrazone

【OSULI】 Sulfin[®] 100mg/Tab

ATC Code : M04AB02

中文名：速復利錠 «東洋»

適應症：慢性痛風性關節炎、間歇性痛風性關節炎。

藥理分類：Uricosuric Agents.

作用機轉：Reduce the serum urate by competitively **inhibiting uric acid reabsorption** in the proximal tubule of the kidney. It lacks anti-inflammatory, analgesic, and diuretic properties.

用法用量：**Administration:** orally, taken with meals or milk.

Indication and dosage regimen:

Hyperuricemia Associated with Gout: Oral:

- Initially, 100-200 mg twice daily during the first week of therapy,
- Full maintenance dosage of 200-400 mg twice daily.
- **Maximum dose: 800 mg/day.**
- Serum urate concentrations usually fall to minimum levels within a few days; once controlled, may attempt to reduce dosage to 200 mg daily in divided doses.

不良反應：噁心、下痢、食慾不振、身倦怠、尿酸結晶。

交互作用：

- **VENLAFAXINE, ESCITALOPRAM, PAROXETINE, DULOXETINE:**
↑ risk of bleeding.

注意事項：1. 還在治療急性痛風時不要開始投與本劑。
2. 腎臟結石或高度腎臟障礙患者禁用。

禁忌：1. 活動性消化性潰瘍。
2. 對本藥或其他 pyrazole 類過敏者。
3. 嚴重肝功能不良。
4. 嚴重腎功能不良。
5. 尿酸性腎臟結石。

懷 孕 期：1. 懷孕婦女使用 Sulfinpyrazone 在臨床上並沒有發現對胚胎或胎兒的有害現象，儘管如此，懷孕的最初三個月應避免使用。
2. Animal teratogenicity studies of pyrazole compounds have resulted in inconclusive data. There are no data from controlled human pregnancy studies. Sulfinpyrazone should be given during pregnancy only when benefit outweighs risk.

授 乳 期：無相關資料。There are no data on the excretion of sulfinpyrazone into human milk.